Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. PaxMedica Inc. (PXMD) Message Board

New Study Challenges Perception of Males Being Mor

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 90
(Total Views: 155)
Posted On: 02/02/2024 5:07:02 PM
Avatar
Posted By: NetworkNewsWire
New Study Challenges Perception of Males Being More Susceptible to Autism

A research team led by Manish Kumar Tripathi, a neuroscientist from the Hebrew University of Jerusalem, has published findings challenging the idea that males are more susceptible to autism than females. The team studied the condition in a mouse model and found that both male and female brains have equal chances of developing the condition.

Autism is a neurological and developmental disorder that affects how individuals learn, communicate, behave and interact with others. While autism is diagnosable at nearly any age, it is typically classified as a “developmental disorder” because its symptoms usually appear in the first two years of an affected individual’s life.

Past studies have found that males are much more likely to develop autism compared to females at an estimated rate of about four males for every one female. Some research has found a smaller discrepancy of 3:1 or 2:1.

Autism is seen, diagnosed and treated primarily as a male disorder, and most of the diagnostic criteria are largely based on how the condition presents in male subjects. However, the recent Hebrew University of Jerusalem study found that both males and females are equally prone to developing autism and provided additional evidence that current data “significantly underestimates” autism rates in females.

Team lead and neuroscientist Manish Kumar Tripathi says the findings underscore the urgent need for male and female participants in autism spectrum disorder (ASD) studies.

This recent study adds to the small but growing body of research questioning whether established understandings of autism spectrum disorder have resulted in a feedback loop that excludes girls and women who qualify for an autism diagnosis. Boys are more likely to be referred for an autism diagnosis, based on mostly male-centric diagnostic criteria, experts say. That has resulted in the aforementioned autism diagnosis rate of four boys for every girl. This, in turn, makes boys the go-to subjects for autism research, locking girls out of the research process and further proliferating the idea that autism mostly affects boys.

Researchers behind the recent study used mouse model lineages with human-based mutations to study synaptic impairment in two autism spectrum disorder models. Interestingly, the research team discovered no difference between brains of females and males that suggested increased susceptibility to autism.

Some past studies have found that girls typically have lower autism rates because the “female protective effect” shields them from presenting traditionally autistic traits. Other studies suggest that girls have higher biological resistance to autism because they require a greater number of mutations to present autistic traits.

For companies that are focusing on developing new treatments for autism spectrum disorder, such as PaxMedica Inc. (NASDAQ: PXMD), the revelation that the condition is as likely to affect females as it does males widens the market that they are likely to address if their R&D efforts are successful.

NOTE TO INVESTORS: The latest news and updates relating to PaxMedica Inc. (NASDAQ: PXMD) are available in the company’s newsroom at https://ibn.fm/PXMD

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer




(0)
(0)




PaxMedica Inc. (PXMD) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us